<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12762">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456807</url>
  </required_header>
  <id_info>
    <org_study_id>109801</org_study_id>
    <nct_id>NCT00456807</nct_id>
  </id_info>
  <brief_title>Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged &gt;/= 26 Years</brief_title>
  <official_title>Complementary Testing to Further Evaluate the Immunogenicity of a GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Aged Over 26 Years Enrolled in Study 104820.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infection with human papillomavirus (HPV) has been clearly established as the central cause
      of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of
      the uterus or womb). This infection may go away by itself, but if it does not go away (this
      is called persistent infection), it can lead in women over a long period of time to cancer
      of the cervix. This study will supplement an ongoing study evaluating the safety, efficacy
      and immunogenicity of the vaccine in women aged 26 years and above. This study will
      therefore assess additional immunogenicity parameters of the vaccine in women from selected
      investigative sites.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Cytokine-positive CD4/CD8 Cells Per Million in Tests Producing at Least 2 Different Cytokines</measure>
    <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The geometric mean and 95% confidence interval of the number of Human Papilloma Virus type 16 (HPV-16) and HPV-18 specific CD4 and CD8 cells producing at least 2 different cytokines is reported per million of CD4 or CD8 T-cells, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of B-cells Per Million Showing a Specific Memory Response for HPV-16 and HPV-18</measure>
    <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The geometric mean and 95% confidence interval of the number of HPV-16 and HPV-18 specific memory B-cells is reported per million of B-cells.
An arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations Above Pre-defined Cut-off Values</measure>
    <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cut-off values assessed include 8 enzyme-linked immunosorbent assay units Per Milliliter (EL.U/mL)for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titers of Anti-HPV-16 and Anti-HPV-18 Antibodies</measure>
    <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers are presented as Geometric Mean Titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) Immunoglobulin G (IgG) Antibodies</measure>
    <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers given as Geometric Mean Titers (GMTs). An arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of Anti-HPV-16 and Anti-HPV-18 Antibodies in Serum and in Cervical Secretion (CVS) Samples</measure>
    <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pearson coefficients of correlation between serum and CVS for anti-HPV-16 and anti-HPV-18 titers standardized for total IgG were calculated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Human Papillomavirus (HPV) Infection</condition>
  <condition>Papillomavirus Vaccines</condition>
  <condition>Cervical Neoplasia</condition>
  <arm_group>
    <arm_group_label>Cervarix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cervarix TM</intervention_name>
    <description>Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.</description>
    <arm_group_label>Cervarix Group</arm_group_label>
    <other_name>GSK Biologicals' HPV-16/18 VLP/AS04 vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A female enrolled in study 104820 and who received three doses of study
             vaccine/control.

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol should be enrolled in the study.

          -  Written informed consent obtained from the subject prior to enrolment in this
             ancillary study.

        Exclusion Criteria:

          -  Pregnancy.

          -  Administration of any HPV vaccine other than that foreseen by the study protocol.

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine since study start.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs since
             study start.

          -  Administration of immunoglobulins and/or any blood products within 90 days preceding
             a blood sampling.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>26 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Delft</city>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <lastchanged_date>March 17, 2011</lastchanged_date>
  <firstreceived_date>April 4, 2007</firstreceived_date>
  <firstreceived_results_date>November 12, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <keyword>Human Papillomavirus</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects enrolled at pre-selected sites in the primary study HPV-015 (NCT00294047) who were in the immunogenicity subset and have received all three doses of vaccine/control were asked to participate in the present ancillary study.</recruitment_details>
      <pre_assignment_details>This ancillary study will consist of supplemental testing of serological and cervical samples obtained at Visit 5 (Month 12) and Visit 6 (Month 18) of the primary study HPV-015 (NCT00294047) from pre-selected sites.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cervarix Group</title>
          <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix Group</title>
          <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="53"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="100"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="40.9" spread="8.44"/>
                <measurement group_id="B2" value="40.3" spread="8.83"/>
                <measurement group_id="B3" value="40.6" spread="8.63"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="53"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="100"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Cytokine-positive CD4/CD8 Cells Per Million in Tests Producing at Least 2 Different Cytokines</title>
        <description>The geometric mean and 95% confidence interval of the number of Human Papilloma Virus type 16 (HPV-16) and HPV-18 specific CD4 and CD8 cells producing at least 2 different cytokines is reported per million of CD4 or CD8 T-cells, respectively.</description>
        <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on subjects from the Total Vaccinated Cohort with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Cytokine-positive CD4/CD8 Cells Per Million in Tests Producing at Least 2 Different Cytokines</title>
            <description>The geometric mean and 95% confidence interval of the number of Human Papilloma Virus type 16 (HPV-16) and HPV-18 specific CD4 and CD8 cells producing at least 2 different cytokines is reported per million of CD4 or CD8 T-cells, respectively.</description>
            <units>cells per million CD4/CD8 T-cells</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>HPV-16 specific CD4 [Month 12] (n=52,46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="877.4" lower_limit="665.0" upper_limit="1157.7"/>
                  <measurement group_id="O2" value="19.5" lower_limit="9.4" upper_limit="40.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-16 specific CD4 [Month 18] (n=52,47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="738.5" lower_limit="512.9" upper_limit="1063.3"/>
                  <measurement group_id="O2" value="22.3" lower_limit="11.3" upper_limit="44.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-16 specific CD8 [Month 12] (n=52,46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.3" upper_limit="3.1"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.2" upper_limit="3.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-16 specific CD8 [Month 18] (n=50,47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.9" lower_limit="1.8" upper_limit="4.7"/>
                  <measurement group_id="O2" value="2.7" lower_limit="1.6" upper_limit="4.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 specific CD4 [Month 12] (n=52,46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="581.2" lower_limit="428.0" upper_limit="789.2"/>
                  <measurement group_id="O2" value="11.5" lower_limit="5.7" upper_limit="23.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 specific CD4 [Month 18] (n=52,47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="300.1" lower_limit="171.9" upper_limit="524.1"/>
                  <measurement group_id="O2" value="16.8" lower_limit="9.1" upper_limit="31.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 specific CD8 [Month 12] (n=52,46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.1" lower_limit="1.3" upper_limit="3.3"/>
                  <measurement group_id="O2" value="1.8" lower_limit="1.1" upper_limit="2.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 specific CD8 [Month 18] (n=50,47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.8" lower_limit="1.7" upper_limit="4.6"/>
                  <measurement group_id="O2" value="4.7" lower_limit="2.6" upper_limit="8.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of B-cells Per Million Showing a Specific Memory Response for HPV-16 and HPV-18</title>
        <description>The geometric mean and 95% confidence interval of the number of HPV-16 and HPV-18 specific memory B-cells is reported per million of B-cells.
An arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification.</description>
        <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on subjects from the Total Vaccinated Cohort with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of B-cells Per Million Showing a Specific Memory Response for HPV-16 and HPV-18</title>
            <description>The geometric mean and 95% confidence interval of the number of HPV-16 and HPV-18 specific memory B-cells is reported per million of B-cells.
An arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification.</description>
            <units>cells per million B-cells</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>HPV-16 specific [Month 12] (n=51,44)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="517.1" lower_limit="361.4" upper_limit="739.9"/>
                  <measurement group_id="O2" value="101.4" lower_limit="45.1" upper_limit="227.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-16 specific [Month 18] (n=51,45)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="304.4" lower_limit="210.0" upper_limit="441.1"/>
                  <measurement group_id="O2" value="33.1" lower_limit="6.7" upper_limit="163.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 specific [Month 12] (n=51,44)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="354.7" lower_limit="253.1" upper_limit="497.1"/>
                  <measurement group_id="O2" value="68.4" lower_limit="27.0" upper_limit="173.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HPV-18 specific [Month 18] (n=51,45)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="301.5" lower_limit="223.9" upper_limit="406.0"/>
                  <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations Above Pre-defined Cut-off Values</title>
        <description>Cut-off values assessed include 8 enzyme-linked immunosorbent assay units Per Milliliter (EL.U/mL)for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
        <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on subjects from the Total Vaccinated Cohort with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations Above Pre-defined Cut-off Values</title>
            <description>Cut-off values assessed include 8 enzyme-linked immunosorbent assay units Per Milliliter (EL.U/mL)for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 [Month 12] (n=52, 45)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 [Month 18] (n=49, 46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 [Month 12] (n=52, 45)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 [Month 18] (n=49, 46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Titers of Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
        <description>Titers are presented as Geometric Mean Titers (GMTs).</description>
        <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on subjects from the Total Vaccinated Cohort with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers of Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
            <description>Titers are presented as Geometric Mean Titers (GMTs).</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 [Month 12] (n=52, 45)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2050.4" lower_limit="1456.1" upper_limit="2887.3"/>
                  <measurement group_id="O2" value="6.9" lower_limit="5.3" upper_limit="9.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 [Month 18] (n=49, 46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1517.1" lower_limit="1067.4" upper_limit="2156.4"/>
                  <measurement group_id="O2" value="7.2" lower_limit="5.4" upper_limit="9.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 [Month 12] (n=52, 45)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="761.4" lower_limit="538.0" upper_limit="1077.5"/>
                  <measurement group_id="O2" value="4.8" lower_limit="3.5" upper_limit="6.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 [Month 18] (n=49, 46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="551.4" lower_limit="387.5" upper_limit="784.6"/>
                  <measurement group_id="O2" value="4.9" lower_limit="3.6" upper_limit="6.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) Immunoglobulin G (IgG) Antibodies</title>
        <description>Titers given as Geometric Mean Titers (GMTs). An arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification.</description>
        <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data. None of the subjects in the Placebo Group had detectable antibodies against HPV-16 at Months 12 and 18 and against HPV-18 at Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) Immunoglobulin G (IgG) Antibodies</title>
            <description>Titers given as Geometric Mean Titers (GMTs). An arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification.</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV16 [Month 12] (n=12, 10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="129.5" lower_limit="58.0" upper_limit="289.2"/>
                  <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV16 [Month 18] (n=26, 20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99.9" lower_limit="48.9" upper_limit="203.8"/>
                  <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV18 [Month 12] (n=12, 10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67.2" lower_limit="28.6" upper_limit="158.0"/>
                  <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV18 [Month 18] (n=26, 20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42.8" lower_limit="23.1" upper_limit="79.6"/>
                  <measurement group_id="O2" value="5.8" lower_limit="5.8" upper_limit="5.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation of Anti-HPV-16 and Anti-HPV-18 Antibodies in Serum and in Cervical Secretion (CVS) Samples</title>
        <description>Pearson coefficients of correlation between serum and CVS for anti-HPV-16 and anti-HPV-18 titers standardized for total IgG were calculated.</description>
        <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated Cohort, only on those subjects from the Cervarix group with CVS sample results available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Correlation of Anti-HPV-16 and Anti-HPV-18 Antibodies in Serum and in Cervical Secretion (CVS) Samples</title>
            <description>Pearson coefficients of correlation between serum and CVS for anti-HPV-16 and anti-HPV-18 titers standardized for total IgG were calculated.</description>
            <units>correlation coefficient</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-HVP-16 (Month 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.903"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti- HPV-16 (Month 18)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.898"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 (Month 12)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.901"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 (Month 18)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.876"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No safety data were collected in the framework of this ancillary study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cervarix Group</title>
          <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No safety data were collected in the framework of this ancillary study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
